Head-to-head evidence
regor GLP-1 vs VRB-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
regor GLP-1
Developed by Regor Pharmaceuticals
NCT06867718 · Phase 2 · completed
The trial randomized 267 participants to four active-dose groups or placebo and masked both participants and investigators. Its primary endpoint was percent change in body weight at Week 36, but the registry does not report whether the comparison met its statistical objective, so the evidence is currently limited to a well-controlled study design with an unknown result.
VRB-101
Developed by Verdiva Bio
NCT07281937 · Phase 2 · completed
The trial randomly assigns participants to VRB-101 or a matching placebo and keeps participants, care providers and assessors all blinded, using percent body weight change, a standard measure for obesity drugs, as its main result. Results have not been posted yet, so whether the weight-loss difference was statistically meaningful is not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: November 2026 · NCT07553299 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: regor GLP-1's landscape · VRB-101's landscape